Abstract

  The outbreak of novel coronavirus from Wuhan, China has become the global concern as more than 2000 people has been died and nearly 75,000 has been proved infected. History showed that, such outbreak is continually happening in every decade or two. Hence, the advancement in science and technology should be prepared of such situation. On the other hand, past studies suggested that the coronavirus outbreak mainly occurred or transmitted from animals and it very crucial to avoid consumption or use of such animals in normal life. The alertness should be strict because the virus is able to change their genetic makeup when it transmits from one animal to the other and, hence the protein target for antiviral agent also need a change. At this situation, it is necessary to find out as much target as possible to use the existing drugs or antiviral agent to control the spread.

Keywords: Coronavirus; Covid-19

References

1. Weiss SR and S Navas-Martin. “Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus”. Microbiology and Molecular Biology Reviews 69.4 (2005):  635-664.
2. Gretebeck LM and K Subbarao. “Animal models for SARS and MERS coronaviruses”. Current Opinion in Virology 13 (2015): 123-129.
3. Wang C., et al. “A novel coronavirus outbreak of global health concern”. The Lancet (2020).
4. Dong N., et al. “Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China”. Bio Rxiv (2020).
5. Wu F., et al. “Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China”. Bio Rxiv (2020).
6. Hu B., et al. “Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus”. PLoS Pathogens 13.11 (2017).
7. Yang XL., et al. “Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus”. Journal of Virology 90.6 (2016): 3253-3256.
8. Thiel V., et al. “Viral replicase gene products suffice for coronavirus discontinuous transcription”. Journal of Virology 75.14 (2001):  6676-6681.
9. Thiel V., et al. “Mechanisms and enzymes involved in SARS coronavirus genome expression”. Journal of General Virology 84.9 (2003): 2305-2315.
10. Adedeji AO and SG “Sarafianos, Antiviral drugs specific for coronaviruses in preclinical development”. Current Opinion in Virology 8 (2014):  45-53.
11. Liang PH. “Characterization and inhibition of SARS-coronavirus main protease”. Current Topics in Medicinal Chemistry 6.4 (2006): 361-376.
12. Ramajayam R., et al. “Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors”. Bioorganic and Medicinal Chemistry 18.22 (2010): 7849-7854.
13. Frieman M., et al. “Yeast based small molecule screen for inhibitors of SARS-CoV”. PLoS one 6.12 (2011).
14. Adedeji AO., et al. “Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses”. Antimicrobial Agents and Chemotherapy (2014): 02994-02914.
15. Huntley CC., et al. “RFI-641, a potent respiratory syncytial virus inhibitor”. Antimicrobial Agents and Chemotherapy 46.3 (2002): 841-847.
16. Simmons G., et al. “Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research”. Antiviral Research 100.3 (2013):  605-614.
17. Bosch BJ., et al. “Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide”. Journal of Virology 82.17 (2008):  8887-8890.
18. Diederich S., et al. “Role of endocytosis and cathepsin-mediated activation in Nipah virus entry”. Virology 375.2 (2008): 391-400.
19. Sung  J., et al. “Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak”. Thorax 59.5 (2004): 414-420.
20. Falzarano D., et al. “Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin”. Scientific Reports 3 (2013): 1686.
21. Booth CM., et al. “Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area”. Journal of the American Medical Association 289.21 (2003): 2801-2809.
22. Muller MP., et al. “Adverse Events Associated with High‐Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory Syndrome. Pharmacotherapy”. The Journal of Human Pharmacology and Drug Therapy 27.4 (2007):  494-503.
23. Uysal B and G Metan. “Bradycardia in a patient with Crimean-Congo hemorrhagic fever related to ribavirin treatment”. Journal of Vector Borne Diseases 49.3 (2012): 193.

Citation

Citation: Prakriti Sharma Ghimire., et al. “Covid-19 Outbreak on The Rise - Anticipating Treatment Strategy". Acta Scientific Microbiology 3.4 (2020): 28-33.

Copyright

Copyright: © 2020 Prakriti Sharma Ghimire., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.